Rallybio Corporation: 2023 Q3 Form 10-Q Summary
Business context and reporting period
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases. Its principal clinical programs are RLYB212, an anti-HPA-1a antibody for prevention of fetal and neonatal alloimmune thrombocytopenia, and RLYB116, a complement C5 inhibitor. Additional programs include RLYB114, RLYB331 and early-stage metabolic disease collaborations.
The filing covers the three and nine months ended September 30, 2023. The financial statements are unaudited and prepared under U.S. GAAP. Rallybio has no approved products and has generated no product revenue.
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $13.3 million, versus $12.1 million | $37.6 million, versus $29.9 million |
| General and administrative expense | $6.1 million, versus $6.8 million | $20.2 million, versus $20.9 million |
| Total operating expenses | $19.4 million, versus $18.9 million | $57.8 million, versus $50.8 million |
| Net loss | $18.4 million, or $0.45 per share | $54.3 million, or $1.35 per share |
| Interest and other income, net | $1.6 million | $4.9 million |
| Cash used in operating activities | Not separately provided | $48.6 million, versus $42.0 million |
Operating margins and gross margins are not meaningful because the company has no product sales. The accumulated deficit was $215.0 million at September 30, 2023. Cash and cash equivalents were $19.2 million, and marketable securities were $102.2 million, for total cash, cash equivalents and marketable securities of approximately $121.4 million. Total assets were $133.2 million and total liabilities were $9.6 million.
Rallybio reported no debt or credit facility. Investing activities provided $10.7 million during the first nine months, primarily because proceeds from maturities of marketable securities exceeded purchases. Financing activities provided $0.1 million. The company invested $1.5 million in its joint venture during the period.
Material changes versus the prior comparable period
- First-nine-month research and development expense increased $7.7 million, primarily due to higher RLYB212 clinical development and manufacturing costs, increased personnel costs and RLYB331 preclinical activity.
- RLYB212 spending increased $9.1 million to $17.2 million for the nine-month period.
- RLYB116 spending increased modestly for the nine-month period but decreased $2.0 million in the third quarter because of lower manufacturing costs.
- RLYB114 spending declined $1.7 million for the nine-month period.
- The prior-year period included $3.1 million of in-process research and development expense related to the acquisition of RLYB331; no comparable expense was recorded in 2023.
- General and administrative expense declined $0.7 million for the nine-month period.
- Interest income increased substantially because of higher yields on cash and marketable securities, partially offsetting higher operating expenses.
- Net cash used in operations increased $6.6 million year over year.
- Shares outstanding at September 30, 2023 were approximately 37.8 million, compared with approximately 37.8 million at December 31, 2022. Pre-funded warrants for up to 3.3 million additional shares remained outstanding and unexercised.
Guidance, outlook, risks and unusual items
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital requirements into the first quarter of 2025, while also stating that liquidity is sufficient for more than 12 months from issuance of the financial statements.
- The company expects to continue incurring significant losses and negative cash flows and will require substantial additional capital to complete development and commercialization of its product candidates.
- Management expects preliminary multiple-dose Phase 1 data for RLYB212 and initial Phase 1 data for RLYB116 in the fourth quarter of 2023.
- Rallybio expects to complete the comprehensive RLYB212 toxicology program in the fourth quarter of 2023 and plans to initiate a Phase 2 dose-confirmation study in the second half of 2024, subject to regulatory discussions and supporting data.
- The FNAIT natural history study plans to screen approximately 7,600 women by the end of 2023 and could support a future single-arm Phase 3 study, subject to regulatory acceptance.
- RLYB212 achieved proof-of-concept in a Phase 1b study, and RLYB116 showed greater than 99% reductions in free C5 concentrations at the two highest doses in a Phase 1 study. These early results may not predict later-stage safety, efficacy or regulatory success.
- Key risks include clinical-trial delays or failure, patient recruitment challenges in rare diseases, adverse events, regulatory uncertainty, reliance on contract research and manufacturing organizations, companion-diagnostic requirements, intellectual-property disputes, competition and the need for additional financing.
- The company has a $100.0 million at-the-market facility under its shelf registration but had not sold shares under the facility as of September 30, 2023. Future equity financing could dilute existing stockholders.
- A $2.0 million refundable advance payment related to a potential business arrangement was returned to the company in November 2023.
- Management reported effective disclosure controls and procedures and no material change in internal control over financial reporting during the quarter. No material litigation was reported.
Important facts for investors to verify
- Reconcile the stated liquidity runway into the first quarter of 2025 with quarterly cash use, planned trial spending and the timing of future capital raises.
- Review fourth-quarter 2023 clinical and toxicology updates for RLYB212 and RLYB116, including safety, pharmacokinetics and regulatory implications.
- Assess whether RLYB212 proof-of-concept results translate into meaningful prevention of FNAIT in pregnant patients and support the planned Phase 2 design.
- Monitor cash burn, marketable-security maturities, the $100.0 million ATM facility and potential dilution from equity issuance and pre-funded warrants.
- Evaluate regulatory requirements for RLYB212 screening or companion diagnostics and whether natural-history data will be accepted for future registrational purposes.
- Track clinical-trial enrollment, contract-manufacturing capacity, supply-chain risks and the company’s ability to retain rights under licensing and collaboration agreements.